Canurta Journal

In May, Canurta presented key research findings at the ALS Drug Development Summit and CannMed 2024, reinforcing its commitment to ALS and neurodegenerative disease innovation. Additional highlights include participation at EFFERVESCENCE, a feature in BIOTECanada’s Insights magazine, preparations for the 2024 ALS Pull, and new educational initiatives from Dr. Ethan Russo.

This week, I had the opportunity to attend the ALS Drug Development Summit in Boston, an event that brought together the brightest minds...

Canurta announced its flagship event, FutureBotanica 2024, to spotlight innovation in botanical drug development. The company also participated in 1871’s Cannabis Innovation Lab, Bloom Burton’s Healthcare Investor Conference, and sponsored the ALS Canada Research Forum. April milestones included progress on nanoparticle formulations, new extraction technology, and a PCA fingerprinting pipeline for quality control.

March marked a month of significant momentum for Canurta, including conditional approval for its Grimsby research facility, strategic MOUs with Algoma University and BasgenBIO, and a new U.S. provisional patent supported by IPON. Additional highlights include upcoming speaking engagements, FilingFlow’s Phase 2 rollout, and new progress in ALS biomarker discovery.

We are pleased to announce a significant transformation in our corporate structure and brand architecture. The organization will now have...

In January, Canurta was selected to speak at CannMed 2024 on new treatments for neurological disorders, joined the Cannabis Innovation Lab, and participated in Arab Health 2024 in Dubai and JP Morgan Healthcare Week. Key R&D milestones included positive ALS model results and acquisition of the Answer ALS dataset to support targeted drug development.

In December, Canurta participated in the 34th International Symposium on ALS/MND in Switzerland and shared key insights from the Global Healthspan Summit in Riyadh. The company continued to progress its ALS formulation, launched branded merchandise, and prepared for its 2024 clinical operations.

In November, Canurta CEO Akeem Gardner joined world leaders at the Hevolution Foundation’s Global Healthspan Summit in Riyadh and presented at Bio-Europe and OBIO’s Investment Summit. The company also progressed R&D with a sublingual strip formulation, ALS toxicity trials, and new bioinformatics applications for ALS and ARDS.

Canurta partners with International Speciality Supply to commercialize Activated Hemp Seed Powder in Q1 2024. The company also released new research on cannabis-derived stilbenes, introduced its automated compliance platform FilingFlow, and completed key R&D milestones ahead of Bio-Europe 2023.

In September, Canurta raised over $4,500 for ALS Canada and placed second in the Pull to End ALS challenge. The company announced a validated global standard for detecting cannflavins in hemp extracts, advanced commercial production, and concluded the first phase of its novel molecule generation project.

In August, Canurta progressed toward commercial readiness through a key production partnership with FSOil, continued fundraising for ALS Canada, and released a new episode of the Canurta Day video series. The team also marked R&D milestones in respiratory therapeutics and QSAR modeling, and celebrated contributions from University of Guelph MBIOT summer students.

Canurta’s June was marked by a successful investor pitch day, new research presentations, and strengthened efforts in ALS and cancer research. Highlights include funding for preclinical work on breast cancer, promising virology and inflammation results from cannflavin testing, and continued development of Canurta’s internal molecule database and blockchain platform.

In May, Canurta presented glioblastoma-focused research at CannMed23, sponsored and spoke at the CSPS Symposium, and celebrated team member Samantha Palloo’s recognition with a national award. Operational progress in Grimsby and new biotech collaborations with University of Guelph continue to support Canurta’s clinical and biosynthesis goals.

In April, Canurta shared its clinical pipeline at ACT Canada and connected with global investors at the Bloom Burton Healthcare Conference. The company also progressed pharmacokinetic trials, advanced IP strategy through NRC IRAP support, and opened eight summer positions to foster emerging talent.

Canurta’s Annual General Meeting outlined key 2023 priorities including preclinical advancement, financing preparation, and asset commercialization. The company also received new NRC IRAP funding for respiratory disease research, was recognized for leadership by The Peak, and marked significant milestones in R&D, bioinformatics, and IT infrastructure.

The Company has received $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC...

We're excited to announce that our CEO, Akeem Gardner, was recently interviewed by the Ontario Centre of Innovation (OCI) about the...

Letter from our CEO I am writing to you today as the CEO of our company in the biotech and agricultural industries. I understand that...

Canurta has officially established its operations in Grimsby, Ontario, received registration for its trademark, and presented its glioblastoma research at BE-STEMM 2023. The company will also present at CannMed '23, continuing to showcase the therapeutic potential of cannabis-derived flavonoids.

Canurta’s R&D team has developed a proprietary flash chromatography method for isolating novel hemp polyphenols and is deploying immobilized-enzyme reactors to produce purified therapeutic compounds. The company also welcomed three new bioinformatics scientists through NRC IRAP funding to support its computer-aided drug design pipeline.